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Abstract
Introduction: Observational studies have shown that glycated haemoglobin (HbA1c) is related to mortality, but the shape of
the association is less clear. Furthermore, disease duration and medication may modify this association. This observational
study explored the association between HbA1c measured in stored erythrocytes and mortality. Secondly, it was assessed
whether disease duration and medication use influenced the estimates or were independently associated with mortality.
Methods: Within the European Prospective Investigation into Cancer and Nutrition a cohort was analysed of 4,345
individuals with a confirmed diagnosis of diabetes at enrolment. HbA1c was measured in blood samples stored up to 19
years. Multivariable Cox proportional hazard regression models for all-cause mortality investigated HbA1c in quartiles as well
as per 1% increment, diabetes medication in seven categories of insulin and oral hypoglycaemic agents, and disease
duration in quartiles.
Results: After a median follow-up of 9.3 years, 460 participants died. Higher HbA1c was associated with higher mortality:
Hazard Ratio for 1%-increase was 1.11 (95% CI 1.06, 1.17). This association was linear (P-nonlinearity =0.15) and persistent
across categories of medication use, disease duration, and co-morbidities. Compared with metformin, other medication
types were not associated with mortality. Longer disease duration was associated with mortality, but not after adjustment
for HbA1c and medication.
Conclusion: This prospective study showed that persons with lower HbA1c had better survival than those with higher
HbA1c. The association was linear and independent of disease duration, type of medication use, and presence of co-
morbidities. Any improvement of HbA1c appears to be associated with reduced mortality risk.
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Glycemic control is the main objective of diabetes management
to reduce risk of complications. Glycated hemoglobin (HbA1c)
provides a measure of average blood glucose levels over the
preceding two to three months and is considered the best
measurement of long-term glycemic control [1]. The American
Diabetes Association (ADA) advises diabetes patients to achieve
and maintain an HbA1c below 7% [1].
The United Kingdom Prospective Diabetes Study Group
(UKPDS) has shown that intensive blood-glucose control reduced
microvascular complications [2] and improvement in glycemic
control across all ranges of achieved HbA1c values, was associated
with a reduced risk of diabetes complications [3]. A meta-analysis
of five randomized controlled trials showed that intensive glycemic
control reduced coronary events but was not associated with
overall mortality compared with standard control [4]. Further-
more, several observational studies showed that elevations in
HbA1c were associated with ischemic heart disease mortality [5],
cardiovascular disease (CVD) [6–8], and total mortality [6,8].
Other studies, however, have suggested that the association
between HbA1c and mortality might be U-shaped: Currie et al.
reported a higher mortality risk in diabetics with observed HbA1c
lower than 7.5% [9] and the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) Study Group suggest that intensive
glycemic control for 3.7 years to target a HbA1c below 6%
increases 5-year mortality from any cause in a group of individuals
with type 2 diabetes [10]. However, this higher mortality risk
associated with lower achieved HbA1c levels could have been due
to other factors: age, disease duration and presence of co-
morbidities should to be taken into account [11–13].
Diabetes medications such as insulin and oral hypoglycemic
agents (OHA) are for most individuals with diabetes the main
therapeutic option for glycemic control [1]. Glycemic regulation is
often easy to achieve in the first few months after diagnosis, but
becomes more difficult as the disease progresses [14]. Both the
ADA and International Diabetes Federation (IDF) recommend
OHA when lifestyle interventions are unable to maintain glycemic
control in type 2 diabetes patients. Metformin is the drug of first
choice, but when insufficient, therapy should be augmented with
additional agents from different classes, and finally insulin therapy.
In type 1 diabetes patients, insulin therapy is the only treatment
option [1,15]. Thus, different classes of medication appear to be
effective at different stages of the disease [16] and type of
medication used will reflect the disease stage.
The objective of this observational study was to investigate the
association between HbA1c measured in stored blood samples and
mortality in individuals with diabetes mellitus. Secondly, it was
explored whether the association was influenced by medication use
and disease duration or whether these factors were independent
mortality risk factors.
Methods
Study design
Within the European Prospective Investigation into Cancer and
Nutrition (EPIC) [17], a sub-cohort was defined of participants
with a confirmed diagnosis of diabetes mellitus at baseline. As has
been described previously [18,19], fifteen EPIC study centers from
six European countries provided additional data on diabetes
diagnosis and medication (Denmark, Germany, Italy, the Nether-
lands, Spain, and Sweden). Self-reports of diagnoses obtained at
baseline were confirmed by additional information sources and
included the following, dependent on the available option in study
centers: contact to a medical practitioner, self-reported use of
diabetes medication, repeated self-report during active follow-up
(only in Potsdam, Germany), linkage to diabetes registries, or
a baseline HbA1c above 6% (measured in Malmo ¨, Sweden only).
Figure 1. Proportions of Medication Use and Co-Morbidities, and HbA1c from Stored Erythrocytes across Deciles of Disease
Duration (years) in 5,837 Individuals with Diabetes.
doi:10.1371/journal.pone.0038877.g001
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This study was conducted according to the guidelines laid down
in the Declaration of Helsinki and was approved by ethical review
boards of the single centres and the International Agency for
Research on Cancer in Lyon, France. All subjects provided written
informed consent.
Study population
Of the initial 7,048 self-reports of diabetes mellitus in the
participating EPIC centers, a total of 6,412 participants were
confirmed to have had diabetes at baseline. Of those, 27 were
excluded due to missing mortality data. HbA1c was measured in
4,345 of the remaining 6,385 participants (excluding all partici-
pants from Denmark). Furthermore, information on diabetes
medication use was available for 4,516 (excluding all participants
from Spain and Denmark) and disease duration for 5,837
participants.
In our data, the missingness of these variables could be
explained by study center, which means they are missing at
random. The assumption for a complete-case analysis is that the
observations are missing completely at random. Thus, performing
statistical analyses only on participants with complete data for
these variables would have led to biased results. Nevertheless,
performing multiple imputation for missing observation is valid
when observations are missing at random; therefore, we created
three different datasets for each exposure variable and applied
multiple imputation on the missing observations among the
covariates [20,21]. Thus, the analytical sample of the three
exposure groups comprised n=4,345 participants for HbA1c,
n=4,516 participants for medication use, and n=5,837 partici-
pants for disease duration.
Table 1. Baseline Characteristics
a of 4,345 Individuals with Diabetes from the European Prospective Investigation into Cancer and
Nutrition across Study Center-Specific Quartiles of HbA1c Measured in Stored Erythrocytes.
Q1 Q2 Q3 Q4
Mean (SE) % Mean (SE) % Mean (SE) % Mean (SE) %
N 1,162 1,054 1,071 1,058
HbA1c, % 6.3 (0.5) 7.3 (0.6) 8.3 (0.9) 10.6 (1.8)
Male participants 51 54 52 51
Age, y 56.4 (7.7) 57.4 (7.0) 57.8 (7.0) 57.3 (6.9)
Disease duration, y 7.0 (7.5) 7.7 (7.9) 9.3 (8.5) 10.5 (8.5)
No medication use 51 37 22 14
Metformin (monotherapy) 5 7 6 4
Metformin (combined) 8 11 13 15
Sulfonamides 17 19 22 23
Other OHA or combinations 5 7 7 7
Insulin and OHA combined 3 5 8 10
Insulin therapy 11 16 23 27
Systolic blood pressure, mmHg 141 (20) 144 (21) 144 (20) 145 (20)
Co-morbidities 10 10 12 12
BMI, kg/m
2 28.4 (4.6) 28.9 (4.8) 29.0 (4.8) 29.4 (4.9)
Smoking status
Never 42 43 40 39
Former 34 34 35 36
Current 23 22 24 24
Physical activity
Inactive 14 14 13 11
Moderately inactive 33 32 30 32
Moderately active 45 46 49 49
Active 8 8 8 8
Education
None 6 7 4 5
Primary school 41 42 41 44
Technical/professional school 23 24 26 24
Secondary school 14 12 14 11
Longer (including University) 16 15 16 15
Abbreviations: BMI, body mass index; OHA, oral hypoglycemic agent.
aContinuous variables are shown as mean (SE) and categorical variables are shown as %.
doi:10.1371/journal.pone.0038877.t001
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HbA1c was measured in erythrocytes of blood which was drawn
at baseline between 1991 and 1998 in 4,345 participants from the
study centers of Germany, Italy, the Netherlands, Spain, and
Sweden. Blood samples were stored at 280uC and a part of EPIC-
NL and EPIC-Italy blood samples was stored at 2196uC. For all
Table 2. Baseline Characteristics
a of 4,516 Individuals with Diabetes Mellitus from the European Prospective Investigation into
Cancer and Nutrition by Type of Medication Use.
Diabetes medication % Age (y)
Mean difference
HbA1c
(%)
b
Disease duration
(y) BMI (kg/m
2)
Co-morbidities
(%)
None 31 56.8 (6.6) 20.7 5.8 (6.1) 29.2 (4.7) 12
Metformin
(monotherapy)
5 57.9 (6.8) 0 6.5 (6.0) 30.4 (4.8) 12
Metformin
(combined)
11 58.6 (7.1) +0.8 9.1 (7.2) 29.6 (4.6) 14
Sulfonamides 19 59.4 (6.9) +0.6 8.3 (6.6) 28.7 (4.5) 18
Combinations or other
OHA
7 57.8 (6.3) +0.3 7.6 (7.0) 29.8 (5.4) 15
Insulin and OHA
combined
7 58.1 (6.0) +0.6 10.7 (8.7) 29.8 (4.9) 14
Insulin therapy 19 55.9 (8.3) +0.9 14.7 (10.8) 27.2 (4.9) 18
Abbreviations: BMI, body mass index; OHA, oral hypoglycemic agent.
aMeans (SE) or percentages are shown;
bMean differences in HbA1c values are given compared with metformin monotherapy.
doi:10.1371/journal.pone.0038877.t002
Table 3. Hazard Ratios (95% CI) of Associations between HbA1c, Diabetes Medication use, Disease Duration and Total Mortality in
Individuals with Diabetes.
Cases PY HR
a 95% CI HR
b 95% CI
HbA1c (n=4,345)
Q1 96 11,075 1 Referent 1 Referent
Q2 100 9,761 1.26 0.93, 1.70 1.16 0.85, 1.58
Q3 114 9,802 1.15 0.86, 1.54 1.03 0.77, 1.39
Q4 150 9,495 2.02 1.53, 2.65 1.77 1.32, 2.36
P-Trend ,0001 ,0001
per 1% increase 460 40,133 1.13 1.08, 1.19 1.11 1.06, 1.17
Diabetes medication (n=4,516)
No medication use 101 12,569 0.53 0.34, 0.81 0.58 0.37, 0.90
Metformin (monotherapy) 30 2,043 1 Referent 1 Referent
Metformin (combined) 68 4,653 0.72 0.46, 1.14 0.65 0.41, 1.04
Sulfonamides 153 7,545 0.82 0.54, 1.24 0.78 0.51, 1.18
Combinations or other OHA 30 2,573 0.76 0.44, 1.30 0.74 0.43, 1.27
Insulin and OHA combined 32 2,692 0.91 0.54, 1.56 0.79 0.46, 1.36
Insulin therapy 130 7,971 0.92 0.60, 1.41 0.76 0.49, 1.04
Disease duration (n=5,837)
,2.0 y 157 13,695 1 Referent 1 Referent
2.0 – 4.6 y 170 13,567 1.01 0.81, 1.27 0.96 0.76, 1.21
4.6 – 9.9 y 191 13,212 1.27 1.02, 1.69 1.06 0.84, 1.34
.9.9 y 190 12,936 1.41 1.10, 1.82 1.08 0.83, 1.41
P-Trend 0.003 0.44
Abbreviations: CI, confidence interval; HR, Hazard Ratio; OHA, Oral Hypoglycemic Agents; PY, person-years.
aModel 1: Age- and center-stratified and adjusted for sex, co-morbidities, physical activity, smoking status, educational attainment, body mass index, and systolic blood
pressure;
bModel 2: Model 1 additionally adjusted for disease duration, diabetes medication use, or HbA1c and storage time when adequate.
doi:10.1371/journal.pone.0038877.t003
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were measured on an auto-analyzer (LX20-Pro, Beckman-
Coulter) in July 2010; inter-assay coefficient of variation was
5.8%. In EPIC-Potsdam, HbA1c was measured with the automatic
ADVIA 1650 analyzer (Siemens Medical Solutions, Erlangen,
Germany) in November 2008. To account for the long-term
storage and differences in time of measurement, statistical analyses
were adjusted for storage time, HbA1c was analyzed in center-
specific quartiles, and models with HbA1c as a continuous variable
were stratified for study center. Values were only interpreted in
relative context, i.e. by ranking. Units are expressed as percentages
of hemoglobin using the National Glycohemoglobin Standardiza-
tion Program (NGSP).
Diabetes-related medication
Information on insulin therapy or use of OHA was either self-
reported at the visit at the study center or obtained during medical
verification. Medication use was classified according to the
Anatomical Therapeutic Chemical (ATC) classification of the
World Health Organization. This information was not available
for the study centers in Spain and Denmark. In addition, the
lifestyle questionnaire included a question on insulin therapy.
When a participant did not report the use of diabetes medication
during the visit at the study center or did not report insulin therapy
in the questionnaire, we assumed the participant did not take
diabetes medication.
Disease duration
Duration since diabetes diagnosis was calculated by subtracting
the self-reported age at diagnosis or, when available, the exact date
of diagnosis supplied by the medical practitioner from the age at
baseline examination. Participants who reported an older age at
diabetes diagnosis than their respective age at recruitment were
excluded from the analyses with disease duration as a main
exposure (n=109). In the other analyses, their disease duration
was set to missing.
Other covariates
Further lifestyle- and health-related variables were collected
using questionnaires which included questions on smoking history,
educational level, physical activity, and medical history including
prevalent heart disease, stroke, and cancer. Weight and height as
well as blood pressure values were measured at the baseline
examination.
Outcome ascertainment
Causes and dates of deaths were ascertained using record
linkages with local, regional, or central cancer registries, boards of
health, or death indexes (Denmark, Italy, the Netherlands, Spain,
and Sweden). Germany identified deceased participants with
follow-up mailings and subsequent inquiries to municipality
registries, regional health departments, physicians, or hospitals.
Mortality data were coded according to the International Classifica-
tion of Diseases, Injuries and Causes of Death, Tenth Revision (ICD-10).
For the cause-specific analyses, deaths due to circulatory diseases
(ICD-10 codes I00-I99), cancer (ICD-10 codes C00-D48), and all
other known causes were grouped accordingly. Deaths where the
specific cause of death was unavailable (n=78) were included in
the overall mortality analyses, but excluded from the cause-specific
analysis.
Figure 2. Adjusted Hazard Ratios of Death according to Glycated Hemoglobin (%) Measured in Stored Erythrocytes among 4,345
Individuals with Diabetes. Solid lines indicate hazard ratios and dashed lines indicate 95% confidence intervals derived from restricted cubic
spline regression, with knots placed at the 5
th,1 0
th,2 5
th,7 5
th,9 0
th, and 95
th percentiles of the distribution, using the 50
th percentile as a reference.
Age- and study center-stratified models were adjusted for sex, storage time, disease duration, diabetes medication use, co-morbidities, physical
activity, smoking status, educational attainment, body mass index, and systolic blood pressure. P value for nonlinearity derived from a Wald Chi-
square test was P=0.15.
doi:10.1371/journal.pone.0038877.g002
HbA1c and Mortality in Diabetes
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38877Statistical analyses
All statistical analyses were performed with SAS, version 9.2,
software (SAS Institute, Inc., Cary, North Carolina). Hazard
Ratios and 95% confidence intervals for mortality were calculated
using Cox proportional hazard models [22]. The proportional
hazard assumption was tested for HbA1c with a Kolmogorov-type
supremum test and was not violated. Centre and age at enrolment
in 1-year categories were entered as stratum variables to control
for differences in questionnaire design, follow-up procedures, and
other non-measured center effects. Participants were followed
from study entry until death, emigration, withdrawal, or the end of
follow-up period. Age was used as the primary time variable with
entry time defined as the subject’s age in years at recruitment and
exit time defined as the subject’s age in years at death or censoring
(lost to follow-up or end of follow-up period). Using age as the
underlying time-scale and additional stratification on age at entry
will control for period and cohort effects [23,24]. All reported P
values are 2 sided.
HbA1c was analyzed continuously and in center-specific
quartiles, using the first as reference. Diabetes medication was
analyzed in categories of no medication, metformin monotherapy,
metformin combined with other OHA, sulfonamides, other OHA
or combinations, insulin and OHA combined, and insulin therapy
(all coded as yes/no). Since metformin (monotherapy) is the
preferred medication for type 2 diabetes [1,15], this was used as
reference. Disease duration was analyzed in quartiles using the first
as a reference. Hazard Ratios were adjusted for sex, co-
morbidities, smoking status (never/former/current), education
(five categories), physical activity (four categories), body mass
index (kg per m
2), and systolic blood pressure (mmHg) (Model 1).
Co-morbidities at baseline were defined as self-reported heart
disease, stroke, cancer, or a follow-up of less than two years, since
individuals with a short follow-up period were likely to have been
severely ill at baseline. Model 2 was additionally adjusted for
disease duration (years), diabetes medication (categorized as
outlined above), or HbA1c (%) and storage time (days) when
adequate. A P value for trend across quartiles of HbA1c and
disease duration was calculated using the median value within
categories as continuous variable. Statistical interaction between
HbA1c, disease duration, and medication use was tested with a log
likelihood ratio test by adding a product term to the model. The
correlation coefficients between disease duration, age at re-
cruitment, and length of follow-up were calculated, since these
are time variables and may therefore lead to multicollinearity
when too strongly correlated.
For HbA1c, the Wald Chi-Square test was used to test for
nonlinearity. Risk for specific causes of death were derived from
competing risk models in which separate regression coefficients for
different causes of death were compared using the Wald Chi-
square test and CI were derived from robust estimates of the
covariance matrix [25,26]. A restricted cubic spline regression
model for the association between HbA1c and mortality was fitted
to provide further insight into the shape of the observed
association. Knots were placed at the 5
th,1 0
th,2 5
th,7 5
th,9 0
th,
and 95
th percentile, and the 50
th percentile was used as a reference
[27]. To test for heterogeneity across countries a Q-test was
performed and I
2 was calculated.
As mentioned previously, there were some missing values in
covariates: proportions of missing data for the HbA1c-analyses
were 12% for medication, 12% for disease duration, 20% for
systolic blood pressure, 7% for physical activity, 1% for
educational attainment, and 2%, 7%, and 10% for self-reported
history of heart disease, stroke, and cancer respectively. We
assumed that these values were missing at random and imputed
them with the multiple imputation technique [21]. All variables
(exposure, outcome, and covariates) included in the Cox pro-
portional hazard models were also included in the procedure. Ten
duplicate datasets were sampled from their predictive distribution
based on the observed data with the missing values replaced by
imputed values. In a sensitivity analysis, the associations between
HbA1c and mortality were compared with estimates from
a complete-case analysis (n=2,983) to investigate whether missing
observations of the covariates influenced the effect estimates. The
same was done for medication use and disease duration.
Results
The 4,345 participants included in the HbA1c-analyses were
followed for a median of 9.3 years. In these years, 460 participants
died: 160 from CVD, 120 from cancer, 102 from other known and
external causes and in 78 the cause of death was unknown.
Table 1 displays general characteristics of study participants
across quartiles of HbA1c. Participants with higher HbA1c had
a longer disease duration compared with those with a lower
HbA1c. Furthermore, participants with a high HbA1c were more
likely to use diabetes medications, in particular insulin and
sulfonamides, have a higher BMI and systolic blood pressure and
Table 4. Hazard Ratios (95% CI) of Associations Between a 1%
-Increase in HbA1c and Total Mortality, Stratified for Several
Diabetes-Related Variables, and Cause-Specific Mortality in
4,345 Individuals with Diabetes Mellitus.
HR
a 95% CI
per 1% increase 1.11 1.06, 1.17
By diabetes
medication
No medication 1.10 0.91, 1.34
OHA 1.13 1.05, 1.21
- Metformin 1.15 1.01, 1.31
- Sulphonamides 1.10 0.99, 1.22
Insulin and OHA 1.64 0.91, 2.94
Insulin therapy 1.14 0.98, 1.32
By disease duration
,3.5 y 1.17 1.02, 1.33
3.5 – 9.9 y 1.09 1.00, 1.20
.9.9 y 1.08 0.99, 1.19
By co-morbidities
With co-morbidities (11%) 1.09 0.96, 1.23
Without co-morbidities (89%) 1.11 1.04, 1.17
Cause-specific
mortality
CVD 1.14 1.05, 1.24
Cancer 1.05 0.95, 1.17
Other known causes 1.21 1.09, 1.35
b
Abbreviations: CI, confidence interval; CVD, cardiovascular diseases; OHA, Oral
Hypoglycemic Agents; HR, Hazard Ratio.
aAge- and center-stratified and adjusted for sex, physical activity, smoking
status, educational attainment, body mass index, systolic blood pressure and
for diabetes medication use, co-morbidities or disease duration when these
were not stratified for.
bP value 0.04 for difference in risk estimate derived from competing risk model
versus cancer mortality.
doi:10.1371/journal.pone.0038877.t004
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participants receiving metformin (monotherapy) had shorter
disease duration, higher BMI, and lower prevalence of comorbid-
ities than participants using other medication types. Those who
did not report medication use had the lowest HbA1c, shortest
disease duration and the lowest prevalence of co-morbidities. In
addition, participants who reported insulin therapy had the highest
HbA1c, longest duration, lowest BMI, and highest proportion of
co-morbidities. In Figure 1, glycemic control, medication use,
and presence of comorbidities are displayed across deciles of
disease duration in years on the x-axis. Medication use, in
particular insulin use, co-morbidities, and HbA1c levels increase
with longer disease duration.
Table 3 shows the HR for total mortality according to HbA1c,
medication use and disease duration. High HbA1c categories were
associated with higher mortality: participants in the highest
quartile had a HR of 2.02 (95% confidence interval (CI): 1.53,
2.65) compared with those in the lowest quartile. Additional
adjustment for disease duration and medication use slightly
attenuated the association. Furthermore, an increment of 1%
across all ranges of HbA1c was associated with a 11% higher
mortality risk. Excluding those who did not report to use diabetes
medication did not change the effect estimates: HR for a 1%
increase was 1.13 (95% CI 1.07, 1.20). Compared with metformin
monotherapy, other medications or combinations were not
differentially associated with mortality. Those who did not report
medication use had a lower mortality risk (Hazard Ratio (HR)
0.53, 95% CI: 0.34, 0.81), even after adjustment for HbA1c and
disease duration. Participants with longer disease duration had an
increased mortality risk: those with duration longer than 9.9 years
had a hazard ratio of 1.41 (95% CI: 1.10, 1.82). This association
disappeared when additional adjusting for HbA1c and medication.
Correlation coefficients were r=0.09 between disease duration
and age at recruitment and r=20.08 for between duration and
follow-up time.
A significant linear trend was observed with death rates when
studying HbA1c across quartiles and the dose-dependent associ-
ation was further confirmed by the restricted cubic spline
regression in Figure 2. P for nonlinearity was 0.74 and mortality
risk seemed to increase continuously with higher HbA1c values.
Furthermore, the higher mortality risk per 1%-increase in HbA1c
was found to be persistent across categories of medication use,
disease duration, and co-morbidities (Table 4). In addition,
HbA1c was statistically significantly associated with a 14% in-
creased risk of CVD mortality and a 21% increased risk of dying
from non-CVD/non-cancer causes. Most frequent causes of death
included in latter category were diabetes mellitus and its
complications, and diseases of the respiratory and digestive system.
No statistical interaction between HbA1c, disease duration, and
HbA1c and medication use was found; PV alues for interaction
were P.0.05. No heterogeneity between countries was found for
the associations between HbA1c and mortality: I
2 was 0% (95%
CI: 0–67%) and Q=2.58 (P=0.063). Results from the complete-
case analysis were comparable to those derived from the multiple
imputation procedure. The hazard ratio for a 1%-increase in the
third adjustment model was 1.08 (95% CI: 1.02, 1.15) in the
complete-case analysis, indicating that missing observations for
any of the covariates did not influence the effect estimates.
Discussion
This prospective study showed that HbA1c measured in stored
erythrocytes was positively linearly associated with mortality in
individuals with a confirmed diagnosis of diabetes. This association
was independent of disease duration, medication use, and presence
of co-morbidities. Disease duration and medication use were not
independently from HbA1c associated with mortality.
We have shown that the association between HbA1c and
mortality was positive and linear across all concentrations in a large
diabetic sample. There was a significant linear trend across
quartiles of HbA1c, the Wald Chi-Square test gave no indication
for nonlinearity of the association, and from the restricted cubic
spline regression no threshold for HbA1c could be detected from
which mortality risk was increased. Recent findings from
a randomized controlled trial [10,28] and an observational study
[9] have suggested that the association between HbA1c and
mortality might be U-shaped, i.e. individuals with low as well as
high HbA1c values have an increased risk of death. Other
observational studies have shown similar results in persons with
diabetes [3,5–8,29,30] and without diabetes [29–32]. Eeg-
Olofsson et al. prospectively investigated HbA1c as a risk factor
for CVD and found that a higher HbA1c was associated with
increased CVD and total mortality, even with longer duration,
previous CVD, and treatment with either OHA or insulin.
Moreover, poor long-term glycemic control was associated with
increased risk of dying from ischemic heart disease in newly
diagnosed diabetes patients [5].
Several randomized controlled trials have investigated the effect
of tight glycemic control (HbA1c target ranging from 6.0–6.5%)
over standard therapy (HbA1c target 7.0–7.9%). Overall, intensive
treatment was associated with reduced CVD incidence, in
particular non-fatal myocardial infarction, but not with total and
CVD mortality [4,11–13]. Although it is not possible to directly
compare achieved HbA1c levels with HbA1c levels observed in
a cohort study, these trials have shown that when studying
glycemic control, it is important to take into account individual
disease characteristics, such as progression, presence of complica-
tions and co-morbidities [10].
Cause-specific analyses showed that a higher HbA1c was
associated with increased risk of mortality due to CVD as well
as due to non-CVD/non-cancer causes. Because the latter
category mainly included death due to diabetes mellitus or its
complications, this would suggest that higher levels of HbA1c are
associated with micro- as well as macrovascular outcomes, which is
in line with existing literature [3,33].
To the best of our knowledge, this is one of the first
observational studies to investigate disease duration as an in-
dependent risk factor for mortality. We have found that with
longer disease duration, medication use and HbA1c increased
accordingly. However, disease duration was not associated with
mortality after adjusting for glycemic control and medication use.
Moreover, higher levels of HbA1c were associated with increased
mortality across all strata of diabetes duration. Thus, disease
duration did not seem to be independently related to mortality in
our study. Diabetes mellitus is a progressive disease and glycemic
control worsens as it advances [14]. Therefore, combinations of
several blood glucose lowering medications are often required to
achieve glycemic control as patients progress through the natural
history of the disease [16]. Risk of diabetes complications increases
with longer disease duration [34] and with poorer glycemic control
[35], but up till now it was unclear whether these two factors are
independent. We found one other study which demonstrated that
that HbA1c was higher in subjects with longer duration of diabetes
[36].
Our findings showed that type and proportion of medication use
differed across disease stage, but medication use in itself did not
seem a mortality risk factor. Paradoxically, compared with
metformin therapy, no associations between medication types
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were taken into account. These findings could have been biased by
misclassification, since diabetes medication use was self-reported at
baseline and information on transitions between treatment regi-
mens during follow-up was not available. Furthermore, recom-
mendations for diabetes medication depend on the individual’s
disease stage [1,15]. As a result, in observational studies where
participants are not randomized to a treatment and the type of
medication used will reflect disease progression. Thus, confound-
ing by indication occurs, i.e. differences in prognostic factors may
exist between type of medication. The UKPDS has shown that
metformin was less effective in controlling plasma glucose at six
months, but the effect was more sustained at three years compared
with sulfonylureas and insulin. Both insulin and sulfonylureas were
shown to have an equal treatment effect over a six-year period, but
metformin had a more favorable effect on CVD risk, which was
possibly mediated through its effect on weight [14]. Furthermore,
metformin has been associated with a lower risk of CVD, total
mortality and cancer incidence compared with sulfonylureas and
insulin [37,38]. Currie et al. showed increased mortality risk for
those taking insulin compared with OHA [9].
Our study benefits from the large sample size, the multi-center
design and the verification of self-reported diabetes diagnoses.
Although the study design could have led to heterogeneity due to
differences in HbA1c measurement and verification of diabetes
diagnoses between countries, we did not detect any. Moreover,
this was taken into account in the statistical analyses as much as
possible by stratifying by center. Further limitations which should
be taken into account in the interpretation of the results are that
diabetes medication and disease duration were mostly self-
reported; therefore, misclassification may have occurred. Second,
no information was available on treatment adherence and whether
the prescribed medication was the most appropriate for the
individual patient. Since it is known that compliance to both OHA
and insulin is poor in many diabetes patients [39], no conclusions
about the efficacy of different medication types can be drawn.
Third, HbA1c was measured in blood samples which were stored
up to 19 years. HbA1c values measured in long-term stored blood
samples have found to be highly reliable [40–42], but small
systematic differences may occur due to hemolysis during storage
[41,42]. However, since measurements were highly reliable,
ranking of people would be unchanged and the relative measures
of association unbiased [41,42]. It was not possible to assess the
direction or magnitude of bias caused by measuring HbA1c in
stored erythrocytes rather than fresh blood samples in our study.
Furthermore, no follow-up information on changes in HbA1c was
available; therefore, we could not evaluate changes in manage-
ment which have likely occurred. However, this study comprises
individuals with diabetes at different ages and different stages of
disease progression, thus covering the diversity of the diabetes
population. Fourth, unfortunately information on presence of
microvascular and macrovascular complications and on type 1
and type 2 diabetes was not available.
In conclusion, this observational study showed that HbA1c from
stored erythrocytes is positively and linearly associated with
mortality in individuals with diabetes mellitus, independent from
disease duration, medication use and presence of co-morbidities.
Any improvement of HbA1c appears to be associated with reduced
mortality risk, also when taking into account disease duration.
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